The Consortium Urges Investors to Vote in Favour of Its Binding Agreement for Finalto at the Playtech General Meeting on 15 July 2021
7.7.2021 08:00:00 EEST | Business Wire | Press release
Finalto S.P.V. Ltd, the consortium led by Barinboim Group and backed by Leumi Partners Limited and Menora Mivtachim Group, together with key members of the Finalto Business' management team (together the "Consortium"), responds to the announcement by another party of non-binding interest in Playtech plc’s (“Playtech”) financial trading division, Finalto Group ("Finalto").
The Consortium wants to provide an update on the risks that Playtech shareholders face in not voting for the Consortium’s binding agreement for Finalto (the “Binding Agreement”) and provide reassurance on the certainty and fair value of the Consortium’s offer. After a lengthy bidding process, the Consortium was selected by Playtech on the value of its bid and also the certainty it provided that the Binding Agreement would complete and pass the stringent regulatory approvals.
The Consortium’s Binding Agreement delivers considerable value and certainty of completing this complex transaction
As announced on 26th May 2021, Playtech agreed to sell Finalto to the Consortium, thereby concluding a lengthy, complicated, regulatory-driven and in-depth sale process which began in 2019.
- In Playtech’s own words, this has been an “elongated and thorough process” and the Consortium was selected taking into account not just the price, but also its “ability to complete the transaction (particularly in light of the Finalto Business’ regulated status in multiple global jurisdictions) and the potential to provide a “clean break” for Playtech.”
- The complexity of this transaction should not be underestimated. To provide an example, the Consortium was required to complete extensive regulatory and KYC requirements before it was even eligible to undergo the main regulatory approval checks, all of which took several months to complete, even for a blue-chip consortium such as this one.
- The level of scrutiny that each member of the Consortium underwent in this transaction was substantially higher than normal. In fact, before being allowed to participate in the sale process, each prospective buyer was subject to a multi-factor review which ranged from regulatory clearance to assurances over proof and source of funds, all to ensure a high certainty that the transaction would close.
- Once the Consortium was approved to negotiate the sale and purchase of Finalto with Playtech, it was also made clear to the Consortium that Playtech would only agree to a very limited set of representations and warranties, which again was highly unusual for a transaction of this size and level of complexity. The Consortium agreed, and what followed was a signed Sale and Purchase Agreement (“SPA”) for Finalto.
Not voting for the Consortium’s Binding Agreement risks destabilising Finalto and its performance
- Contrary to what was implied in Gopher Investments’ (“Gopher”) statement, shareholders should understand that due to certain binding terms of the SPA, Playtech is unable to engage with any alternative bidders straight away, even if the shareholders vote against the Consortium’s bid. Moreover, any subsequent sale process will take many months to conclude, during which time Finalto will be – yet again – subject to considerable uncertainty. By the Consortium’s conservative estimation, another bidding process will not be concluded until late 2022 at the earliest.
- Additionally, under the terms of the SPA, should the SPA be terminated in the event that shareholders of Playtech do not approve the Consortium’s Binding Agreement, Playtech will be required to pay the Consortium a consideration of $8.8m in the event that a sale transaction is entered into with a third party within the 12 months after termination of the SPA at a value in excess of $200m.
- It seems quite certain that another lengthy sale process will likely have a highly destabilising and damaging impact on the Finalto business and its workforce, which has already been subject to very aggressive market speculation and whose performance is already under considerable pressure due to factors beyond Finalto’s control such as an uncertain trading environment, the impact of the global pandemic, the ever-changing regulatory nature of the industry and the drawn out sale process since 2019, which has taken up extensive management time already.
Questionable lack of transparency from bidding party undermines certainty of its non-binding indicative offer
The non-binding indicative offer from Gopher presents considerable uncertainty for the Playtech shareholders. Little if anything is known about Gopher, the source of its funds and its ultimate controlling party. What Gopher has purportedly shared about itself is:
- It was registered in the Cayman Islands just days ago.
- Gopher is being advised by TT Bond Partners (“TTB”) and its Hong Kong regulated affiliate, TTB Partners Limited, all of which are registered under the very same address in Hong Kong.
- The little that is known about TTB is that it specializes in, and markets itself as, an investment advisor principally focused on linking Chinese investors with foreign deals. Any acquisition by an entity controlled out of China is likely to raise material regulatory concerns and will be subject to very close scrutiny.
- Gopher has recently acquired just shy of 5% of Playtech plc’s shares, the threshold requiring Gopher to disclose extensive information about itself to regulators.
- To date, no information has been made available as to the identity(s) of Gopher’s ultimate beneficial ownership, those who control Gopher, or Gopher’s source of funds.
- It should also be noted that given the sale process was public and has been going on for months, the timing of Gopher’s approach raises suspicion about their intentions. Gopher could have participated in the process when it was live.
THE CONSORTIUM URGES INVESTORS TO VOTE IN FAVOUR OF ITS BINDING AGREEMENT TO ACQUIRE FINALTO AT THE PLAYTECH GENERAL MEETING ON 15 JULY 2021
The Consortium seeks to stress to the Playtech shareholders that the Binding Agreement, which was unanimously supported by Playtech’s board of directors, represents considerable value for Playtech shareholders. Furthermore:
- The Binding Agreement provides Playtech shareholders with near term certainty of completion following a lengthy and arduous sale process.
- There is no certainty that the Consortium would be prepared to proceed with any acquisition should its Binding Agreement not be approved at the General Meeting on 15th July 2021.
- Voting in favour of the Consortium’s Binding Agreement ensures Playtech’s receipt of the considerable Binding Agreement proceeds in the near future, thereby equipping Playtech with additional resources for reinvestment in its core gambling business, and likewise ending a lengthy, costly and distracting sale process.
- Voting in favour of the Consortium’s Binding Agreement removes the considerable risk, delay and additional costs associated with yet another sale process. In fact, the Consortium has already submitted mandatory change of control applications in multiple jurisdictions where Finalto operates to expedite the closing of the Binding Agreement.
- From the outset of the transaction, the Consortium’s Binding Agreement was and remains fully financed with immediately available proceeds.
- The Consortium is made up of three blue chip multinational organisations, namely, the Barinboim Group, an established investment firm that has a track record of acquiring and growing successful global media companies, Leumi Partners Limited, the merchant and investment banking arm of Bank Leumi (TASE: LUMI), one of the two largest banking groups in Israel, and Menora Mivtachim Group, an Israeli insurance and finance group.
Shareholders have a simple decision at the General Meeting on 15th July 2021:
VOTE IN FAVOUR OF THE CONSORTIUM’S FULLY FUNDED AND BOARD-APPROVED BINDING AGREEMENT – REVIEWED BY PLAYTECH’S FINANCIAL ADVISER AND RECOMMENDED BY PLAYTECH – PROVIDING CONSIDERABLE VALUE, NEAR TERM COMPLETION AND CERTAINTY FOR SHAREHOLDERS AND THE PLAYTECH BUSINESS.
OR risk being left in a predicament where there is no firm bid for Finalto and only speculative interest from an unknown entity and no certainty that any transaction will be completed in 2022, with all the costs, delay, uncertainty, and destabilisation for Playtech, the Finalto Business and Playtech shareholders.
About the Consortium
The Consortium is a company incorporated in Israel, established for the purpose of acquiring the Finalto Business. The Consortium is being funded by a group consisting of Barinboim Group, Leumi Partners Limited and Menora Mivtachim Group and by senior secured debt financing from The Phoenix Insurance Company Limited and certain of its affiliates. The Consortium will be supported by key members of the Finalto Business' management team that will transfer with the Finalto Business, including Ron Hoffman (Chief Executive Officer of the Finalto Business) and Liron Greenbaum (Chief Operations Officer of the Finalto Business).
Barinboim Group is a private equity and venture capital firm based in Tel Aviv. Barinboim Group invests in companies operating in the media sectors.
Leumi Partners Limited is the merchant and investment banking arm of Bank Leumi (TASE: LUMI), one of the two largest banking groups in Israel. Leumi Partners Limited is based in Tel Aviv and offers direct equity investment in sectors such as technology media and telecom, consumer & retail, and healthcare. Leumi Partners Limited's line of business includes conducting investments and providing services such as underwriting, financial analysis and research, strategic advice, mergers & acquisitions, and raising equity and debt.
Menora Mivtachim Group is one of Israel's five largest insurance & finance groups. The group specializes in asset management, manages the largest pension fund in Israel - and is the largest General Insurer in Israel and the market leader in Motor Insurance sector. The group operates through its subsidiaries, in all sectors of Life Insurance, Long/Mid/Short -Term Savings, General Insurance and Health Insurance. In addition, the group is active in the capital markets and finance sectors, including, Financial Portfolio Management, Underwriting and worldwide real estate investments.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005841/en/
Contact information
For further information:
Investors:
Investor Update
Tony Quinn +44 (0)7790 485 935 tquinn@investor-update.com
Patrick Mitchell +44 (0)7974 079 785 pmitchell@investor-update.com
Media:
Kepler Communications
Charlotte Balbirnie +44 (0)7989 528421 cbalbirnie@keplercomms.com
Caroline Villiers +44 (0)7808 585184 cvilliers@keplercomms.com
The Consortium:
Ishai Drori finalto@bgroup.co.il
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
